logo-loader
viewANGLE PLC

ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system.

Not only have they discovered a method of successfully culturing the cancer cells from blood samples taken using Parsortix, they have also designed a work flow for the process.

Quick facts: ANGLE PLC

Price: 57 GBX

AIM:AGL
Market: AIM
Market Cap: £98.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ANGLE PLC opens up potential route to market for Parsortix platform

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), discusses with Proactive their significant new collaboration with healthcare giant Abbott Laboratories. The two will be working on a metastatic breast cancer study. Abbott will provide its proprietary PathVysion HER-2 DNA FISH...

on 6/2/18

2 min read